Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Post by drjekylon Jul 31, 2017 6:26pm
226 Views
Post# 26530887

financials

financialsso, i just had me a lookie lou and found the following:

 

a) During the period ended May 31, 2017, the Company paid BrainBio Inc. (a company controlled by the incoming President and CEO (“CEO”)) of the Company $78,335 (May 31, 2016: $nil) pursuant to a consulting agreement for services and for acting in his capacity as CEO. The Company also incurred benefits expense of $3,010 (May 31, 2016: $nil). 

 

b) During the period ended May 31, 2017, the Company paid the former President and CEO (currently Executive Chairman of the Board of Directors) of the Company $42,000 (May 30, 2016: $42,000) pursuant to a salary contract for services and for acting in his capacity as CEO and Executive Chairman of the Board of Directors. The Company also incurred payroll benefits expense of $3.010 (May 31, 2016: $nil) and $2,059 (May 31, 2016: $2,497) attributed to the former CEO. As at May 31, 2017, the Company owed $4,776 (May 31, 2016: $nil) to the former CEO, which is unsecured, non-interest bearing and with no repayment terms. 


drj!



Bullboard Posts